← Digital Health Decoded / Issue #9

Issue #9 · June 24, 2026 · 5-minute read Read Issue #9 on Beehiiv →

Continuous Health Intelligence

From Continuous Monitoring to Personalized Intervention

⚡ Quick Hits

Omada’s first public year holds up — Q1 2026 (reported May 7): revenue $78M, +42% YoY; members past 1M (+51%); first positive Q1 adjusted EBITDA; guidance raised; now tied to all three major PBMs. Proof the GLP-1 wrap-around model from Issue 6 can scale — though two Cigna-linked partners still drive much of revenue.

🔗 Omada · MobiHealthNews

Cuffless blood pressure goes commercial — Aktiia’s FDA-cleared OTC Hilo Band reaches the U.S. in 2026; Samsung switched on Galaxy Watch BP for U.S. users in March. Both optical, both still need cuff calibration, both labeled wellness, not diagnosis — the line the FDA just reaffirmed in its Whoop decision (see Policy & Payer).

🔗 Aktiia / MobiHealthNews · Samsung

OTC glucose without a clinic — Ultrahuman’s M2 Live launched June 18 on Abbott’s OTC Lingo sensor (from $99/mo, no Rx), joining Dexcom Stelo on the no-fingerstick shelf. Still a filament under the skin — “needleless” glucose stays a myth (table below).

🔗 Ultrahuman · Engadget

🔗 OTC CGM landscape — GoodRx · FDA warning — AARP · Whoop · Huawei

AI shifts from assistant to infrastructure — the quarter’s standout wasn’t a chatbot but embedded care ops: Omada credited AI-enabled care for margin gains. The biggest AI wins may be invisible — the layer interpreting the continuous stream.

🔗 Omada Q1 transcript

“Between-visit” becomes a category — Omada now brands itself a between-visit provider; the action is in the space where adherence and behavior actually happen, not the appointment.

🔗 Omada

FDA backs off Whoop — and draws the wellness line — the agency rescinded its 2025 warning letter this week after Whoop adjusted its Blood Pressure Insights feature (it reworked the dial boundaries so the reading doesn’t look clinical), confirming that BP estimates framed as wellness sit outside device regulation under its January 2026 guidance — the same logic now shielding Samsung, Aktiia, and every cuffless player. In parallel, FDA floated draft performance-testing standards for cuffless devices making clinical claims, extending the Issue 7 standards thread to the wrist. The WHOOP convergence we opened on in Issue 1 just got its rulebook: wellness ships freely; medical claims must validate.

🔗 MedTech Dive · FDA closeout letter · FDA / HHS draft guidance

First CAR-T for a solid tumor — China’s NMPA approved CARsgen’s satri-cel (June 22) for Claudin18.2-positive, HER2-negative advanced gastric/GEJ cancer, 3rd-line and beyond. A real milestone with modest absolute numbers (median PFS 3.25 vs 1.77 mo; OS 7.9 vs 5.5 mo). A decade of CAR-T confined to blood cancers just cracked — and it happened in China, not the U.S.

🔗 CARsgen · FiercePharma · OncLive

---

💡 Maria’s Take: The Home Layer Splits in Two

Issue 8 left one question open — episodic or continuous? This week answered it: both, layered.

Two lanes are forming. Continuous sensors (cuffless BP, OTC CGM) catch the trend and the variability. On-demand home labs — the Noom $125 Tasso+ kit from Issue 8, decentralized blood collection feeding a central lab — catch what sensors can’t: lipids, ApoB, hormones, inflammation.

Neither wins alone. The panel tells you where you are; the sensor tells you where you’re heading. The prize isn’t a sensor or a kit — it’s the loop between them: stream → flag → confirm → coach → retest.

---

📚 One Resource Worth Reading

Cuffless Blood Pressure Technologies in Wearable Devices — American Heart Association scientific statement. Why these wrist devices are promising and not yet ready to diagnose — essential before you trust, or build on, a cuffless number. Read the statement →

© PolyOMIC Solutions. All Rights Reserved.